PFIZER Aktie

 

AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year....

The latest trading day saw Pfizer (PFE) settling at $29.21, representing a +2.96% change from its previous close....

Senior appointments from Pfizer, Novartis, Arbor Biotechnologies, and Orum Therapeutics bring preclinical development, structural biology, and portfolio strategy depth as MindWalk prepares its programs for preclinical efficacy studiesBOSTON--(BUSINESS WIRE)--$HYFT #ai--MindWalk Holdings Corp. (NASDAQ: HYFT) (“MindWalk” or the “Company”), a Bio-Native AI company, today announced three senior appointments that strengthen its Boston-based development leadership as the Company's pipeline advances toward preclinical efficacy studies. Zachary Maben, PhD, joins as Director, Antigen Discovery & Protein Engineering, from Arbor Biotechnologies and previously Pfizer. Joanne Lim, PhD, joins as Director, Preclinical Development, from Orum Therapeutics and previously Codiak Biosciences and Novartis. Shuji Sato, PhD, Vice President, Innovative Solutions, a MindWalk veteran with prior roles at Pfizer and Dragonfly Therapeutics, expands his responsibilities to include the Company's pipeline. Preclinical efficacy...

Under the partnership, Enodia Therapeutics will handle initial discovery work to identify, refine, and advance small-molecule candidates directed at multiple targets. Pfizer will take full responsibility for subsequent The post Pfizer partners with Enodia Therapeutics in $500m drug deal appeared first on Pharmaceutical Business review....

Johnson & Johnson (NYSE:JNJ) stock is at $249.55, down 5% early in the session. The company raised its full-year outlook in the same release that showed its reported profit falling under one-time charges. Meanwhile, Eli Lilly (NYSE:LLY) stock is at $1,174.46, down 0.7%, representing a much milder decline than Johnson & Johnson stock. At the […]...

Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030....

Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...

PFE moves above its 50-day SMA as newer drugs, oncology and obesity treatments fuel growth prospects, but declining COVID sales and patent expirations pose challenges....

Kraft Heinz, Pfizer, Verizon, and Dow all flash yields above 4%, but behind each payout sits a mix of impairments, rising debt, and shrinking sales that could turn a tempting income stream into a costly trap....

You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb....

Pfizer's dividend yield has climbed well above what most blue-chip drugmakers offer, and the reason behind that gap matters far more than the number itself....

Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies....

Moderna (NASDAQ:MRNA) stock trades at $207.80, up 5%, after its addition to the NASDAQ 100 took effect. That entry places a company once valued as a COVID-19 vaccine maker inside one of the most widely tracked growth benchmarks in the market. Meanwhile, Pfizer (NYSE:PFE) stock is at $28.02, up 0.7%, a far smaller gain than […]...

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects....

NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Pfizer von 28 auf 30 US-Dollar angehoben, aber die Einstufung auf "Neutral" belassen. Seine Schätzungen für die Quartalszahlen des Pharmakonzerns am 3. November lägen moderat über ......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Cantor Fitzgerald just bumped price targets on Eli Lilly, AbbVie, Merck, and Pfizer, but higher targets do not mean equal conviction. The firm's split between Overweight and Neutral ratings reveals a sharp divide in where analysts see real upside and where near-term catalysts could disappoint....

Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories....

PFE's oncology growth in Q3 hinges on key drug sales, biosimilars and progress across a late-stage pipeline....

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report....